Literature DB >> 19882251

Improved quality control metrics for cascade impaction measurements of orally inhaled drug products (OIPs).

Terrence P Tougas1, David Christopher, Jolyon P Mitchell, Helen Strickland, Bruce Wyka, Mike Van Oort, Svetlana Lyapustina.   

Abstract

This study of aerodynamic mass-weighted particle size distribution (APSD) data from orally inhaled products (OIPs) investigated whether a set of simpler (than currently used) metrics may be adequate to detect changes in APSD for quality control (QC) purposes. A range of OIPs was examined, and correlations between mass median aerodynamic diameter and the ratio of large particle mass (LPM) to small particle mass (SPM) were calculated. For an Andersen cascade impactor, the LPM combines the mass associated with particle sizes from impactor stage 1 to a product-specific boundary size; SPM combines the mass of particles from that boundary through to terminal filter. The LPM-SPM boundary should be chosen during development based on the full-resolution impactor results so as to maximize the sensitivity of the LPM/SPM ratio to meaningful changes in quality. The LPM/SPM ratio along with the impactor-sized mass (ISM) are by themselves sufficient to detect changes in central tendency and area under the APSD curve, which are key in vitro quality attributes for OIPs. Compared to stage groupings, this two-metric approach provides better intrinsic precision, in part due to having adequate mass and consequently better ability to detect changes in APSD and ISM, suggesting that this approach should be a preferred QC tool. Another advantage is the possibility to obtain these metrics from the abbreviated impactor measurements (AIM) rather than from full-resolution multistage impactors. Although the boundary is product specific, the testing could be accomplished with a basic AIM system which can meet the needs of most or all OIPs.

Mesh:

Substances:

Year:  2009        PMID: 19882251      PMCID: PMC2799578          DOI: 10.1208/s12249-009-9312-4

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  8 in total

1.  Considerations for the development and practice of cascade impaction testing, including a mass balance failure investigation tree.

Authors:  Dave Christopher; Paul Curry; Bill Doub; Kenneth Furnkranz; Martin Lavery; Karl Lin; Svetlana Lyapustina; Jolyon Mitchell; Brian Rogers; Helen Strickland; Terrence Tougas; Yi Tsong; Bruce Wyka
Journal:  J Aerosol Med       Date:  2003

2.  General model for nutritional responses of higher organisms.

Authors:  P H Morgan; L P Mercer; N W Flodin
Journal:  Proc Natl Acad Sci U S A       Date:  1975-11       Impact factor: 11.205

Review 3.  Analysis of cascade impactor mass distributions.

Authors:  Craig Dunbar; Jolyon Mitchell
Journal:  J Aerosol Med       Date:  2005

4.  Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols, part 1: background for a statistical method.

Authors:  Wallace P Adams; David Christopher; Douglas S Lee; Beth Morgan; Ziqing Pan; Gur Jai Pal Singh; Yi Tsong; Svetlana Lyapustina
Journal:  AAPS PharmSciTech       Date:  2007-01-19       Impact factor: 3.246

5.  The abbreviated impactor measurement (AIM) concept: part 1--Influence of particle bounce and re-entrainment-evaluation with a "dry" pressurized metered dose inhaler (pMDI)-based formulation.

Authors:  J P Mitchell; M W Nagel; V Avvakoumova; H MacKay; R Ali
Journal:  AAPS PharmSciTech       Date:  2009-03-12       Impact factor: 3.246

6.  The abbreviated impactor measurement (AIM) concept: part II--Influence of evaporation of a volatile component-evaluation with a "droplet-producing" pressurized metered dose inhaler (pMDI)-based formulation containing ethanol as cosolvent.

Authors:  J P Mitchell; M W Nagel; V Avvakoumova; H MacKay; R Ali
Journal:  AAPS PharmSciTech       Date:  2009-03-17       Impact factor: 3.246

7.  Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: comparison of Andersen 8-stage cascade impactor, next generation pharmaceutical impactor, and model 3321 Aerodynamic Particle Sizer aerosol spectrometer.

Authors:  Jolyon P Mitchell; Mark W Nagel; Kimberly J Wiersema; Cathy C Doyle
Journal:  AAPS PharmSciTech       Date:  2003-10-22       Impact factor: 3.246

8.  Aerodynamic sizing of metered dose inhalers: an evaluation of the Andersen and Next Generation pharmaceutical impactors and their USP methods.

Authors:  Akihiko Kamiya; Masahiro Sakagami; Michael Hindle; Peter R Byron
Journal:  J Pharm Sci       Date:  2004-07       Impact factor: 3.534

  8 in total
  3 in total

1.  Relative precision of inhaler aerodynamic particle size distribution (APSD) metrics by full resolution and abbreviated andersen cascade impactors (ACIs): part 1.

Authors:  Jolyon P Mitchell; Mark W Nagel; Cathy C Doyle; Rubina S Ali; Valentina I Avvakoumova; J David Christopher; Jorge Quiroz; Helen Strickland; Terrence Tougas; Svetlana Lyapustina
Journal:  AAPS PharmSciTech       Date:  2010-05-18       Impact factor: 3.246

2.  Product lifecycle approach to cascade impaction measurements.

Authors:  Terrence P Tougas; Dave Christopher; Jolyon Mitchell; Svetlana Lyapustina; Michiel Van Oort; Richard Bauer; Volker Glaab
Journal:  AAPS PharmSciTech       Date:  2011-02-01       Impact factor: 3.246

Review 3.  In Vitro Testing for Orally Inhaled Products: Developments in Science-Based Regulatory Approaches.

Authors:  Ben Forbes; Per Bäckman; David Christopher; Myrna Dolovich; Bing V Li; Beth Morgan
Journal:  AAPS J       Date:  2015-05-05       Impact factor: 4.009

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.